$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
Analysis of the efficacy and adverse reactions of rubitidine in the treatment of small cell lung cancer
2025-10-19 11:44:20
Check Details
The mechanism of acquiring resistance to crizotinib in ALK-rearranged lung cancer
2025-10-19 11:44:20
Check Details
Serious adverse reactions during treatment with crizotinib (Xalkori)
2025-10-19 11:44:20
Check Details
Analysis of the efficacy and adverse reactions of ceritinib in the treatment of advanced ALK-positive lung cancer
2025-10-19 11:44:20
Check Details
The most common adverse reactions of nivolumab in the treatment of non-small cell lung cancer
2025-10-19 11:44:20
Check Details
Analysis of the efficacy and side effects of ramucirumab in the treatment of lung cancer
2025-10-19 11:44:20
Check Details
Side effects and treatment methods of alectinib in the treatment of lung cancer
2025-10-19 11:44:20
Check Details
Analysis of the efficacy and adverse reactions of alectinib in the treatment of ALK-positive lung cancer
2025-10-19 11:44:20
Check Details
Side effects and treatment methods when using lorlatinib to treat non-small cell lung cancer
2025-10-19 11:44:20
Check Details
Side effects and treatment methods of Xalkori in the treatment of ALK-positive non-small cell lung cancer
2025-10-19 11:44:20
Check Details
How many days will the side effects of Duozerun's treatment of lung cancer last?
2025-10-19 11:44:20
Check Details
What are the side effects of Crizotinib Capsules
2025-10-19 11:44:20
Check Details
1
2
...
4095
4096
4097
4098
4099
4100
4101
...
4157
4158
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Cabozantinib Capsules: A Multi-Targeted Therapy for Progressive Medullary Thyroid Cancer
2
Lorlatinib: Mechanism, Advantages, and Key Considerations of Third-Generation ALK Inhibitor Therapy in ALK-Positive NSCLC
3
Pemigatinib Side Effects Explained: Managing Adverse Reactions of FGFR-Targeted Therapy in Cholangiocarcinoma
4
Selpercatinib: Before or After Meals? A Complete Guide to RET-Targeted Therapy Administration
5
Mitotane for Adrenocortical Carcinoma: Dosing Guidelines and Therapeutic Drug Monitoring
6
Leflunomide and Ocular Adverse Effects: Risk Awareness and Clinical Guidance
7
Clinical Management of Acquired Resistance to Garsorasib (KRAS G12C Inhibitor)
8
Chemical Structure of Capivasertib: A Novel AKT Inhibitor
9
Capivasertib: An AKT Inhibitor for Breast and Prostate Cancer
10
Global Update 2026: Selumetinib (KOSELUGO) Expands Indication to Adult NF1-PN and Clinical Management Strategies
11
Lenvatinib Safety Guide: Baseline Assessment & Adverse Reaction Management
12
Inluriyo (Imlunestrant): Oral SERD for ER+/HER2- Breast Cancer with ESR1 Mutations